Total Hip Arthroplasty in Multiple Sclerosis

Nico Maximilian Jandl; Tobias Schmidt; Andreas Niemeier

doi:10.1055/a-1004-3366

Zeitschrift für Orthopädie und Unfallchirurgie, Inhaltsverzeichnis

Z Orthop Unfall 2020; 158(02): 188-193
DOI: 10.1055/a-1004-3366

Review/Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Total Hip Arthroplasty in Multiple Sclerosis

Artikel in mehreren Sprachen: English | deutsch

Autor*innen

Nico Maximilian Jandl

¹Department of Orthopedics, University Medical Center Hamburg-Eppendorf, Hamburg

²Department of Osteology and Biomechanics IOBM, University Medical Center Hamburg-Eppendorf, Hamburg
Tobias Schmidt

²Department of Osteology and Biomechanics IOBM, University Medical Center Hamburg-Eppendorf, Hamburg

³Department of Orthopedics and Traumatology, Reinbek Hospital St Adolf Stift, Reinbek
Andreas Niemeier

¹Department of Orthopedics, University Medical Center Hamburg-Eppendorf, Hamburg

³Department of Orthopedics and Traumatology, Reinbek Hospital St Adolf Stift, Reinbek

Abstract

Systemic neurological disease represents a risk factor for complications after total hip arthroplasty (THA), especially for dislocation, infections, gait disorders and fall-related periprosthetic fractures. There is little specific literature on total hip arthroplasty in patients with multiple sclerosis. However, increased revision rates have been reported, which are in part due to dislocations. Implants with increased dislocation safety, e.g. tripolar acetabular systems, can represent a reasonable alternative. Due to gait disorders and a higher prevalence of osteoporosis, specific osteological evaluation and treatment should be considered to prevent periprosthetic fractures. This short review summarizes the current literature on total hip arthroplasty in patients with multiple sclerosis.

Key words

total hip arthroplasty - total hip replacement - MS - multiple sclerosis

Volltext

Referenzen

References/Literatur
1 Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 2013; 19(2 Suppl.): S15-S20
2 Petersen G, Wittmann R, Arndt V. et al. [Epidemiology of multiple sclerosis in Germany: regional differences and drug prescription in the claims data of the statutory health insurance]. Nervenarzt 2014; 85: 990-998 doi:10.1007/s00115-014-4097-4
3 Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517 doi:10.1016/S0140-6736(08)61620-7
4 Marrie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. Continuum (Minneap Minn) 2013; 19: 1046-1057 doi:10.1212/01.CON.0000433284.07844.6b
5 Newman JM, Naziri Q, Chughtai M. et al. Does multiple sclerosis affect the inpatient perioperative outcomes after total hip arthroplasty?. J Arthroplasty 2017; 32: 3669-3674 doi:10.1016/j.arth.2017.07.006
6 Ce P, Gedizlioglu M, Gelal F. et al. Avascular necrosis of the bones: an overlooked complication of pulse steroid treatment of multiple sclerosis. Eur J Neurol 2006; 13: 857-861 doi:10.1111/j.1468-1331.2006.01375.x
7 Carulli C, Nistri L, Bracco L. et al. A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis. Clin Cases Miner Bone Metab 2015; 12: 257-259 doi:10.11138/ccmbm/2015.12.3.257
8 Sahraian MA, Yadegari S, Azarpajouh R. et al. Avascular necrosis of the femoral head in multiple sclerosis: report of five patients. Neurol Sci 2012; 33: 1443-1446 doi:10.1007/s10072-011-0914-8
9 Zhang NF, Li ZR, Wei HY. et al. Steroid-induced osteonecrosis: the number of lesions is related to the dosage. J Bone Joint Surg Br 2008; 90: 1239-1243 doi:10.1302/0301-620X.90B9.20056
10 Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987; 1: 902-906 doi:10.1016/s0140-6736(87)92870-4
11 Kale N, Agaoglu J, Tanik O. Correlation of cumulative corticosteroid treatment with magnetic resonance imaging assessment of avascular femoral head necrosis in patients with multiple sclerosis. Neurol Int 2010; 2: e17 doi:10.4081/ni.2010.e17
12 Marrie R, Horwitz R, Cutter G. et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008; 14: 1091-1098 doi:10.1177/1352458508092263
13 Quinlan ND, Chen DQ, Werner BC. et al. Patients with multiple sclerosis are at increased risk for postoperative complications following total hip and knee arthroplasty. J Arthroplasty 2019; 34: 1606-1610 doi:10.1016/j.arth.2019.04.022
14 Newman JM, Khlopas A, Sodhi N. et al. Are adverse outcome rates higher in multiple sclerosis patients after total hip arthroplasty?. Bone Joint J 2018; 100-B: 875-881 doi:10.1302/0301-620X.100B7.BJJ-2017-1569.R1
15 Rondon AJ, Schlitt PK, Tan TL. et al. Survivorship and outcomes in patients with multiple sclerosis undergoing total joint arthroplasty. J Arthroplasty 2018; 33: 1024-1027 doi:10.1016/j.arth.2017.10.056
16 Gutman JM, Kim K, Schwarzkopf R. et al. Total hip and knee arthroplasty in patients with multiple sclerosis. Int J MS Care 2018; 20: 244-250 doi:10.7224/1537-2073.2017-093
17 Amatya B, Khan F, Galea M. Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev 2019; (01) CD012732
18 Weinstock-Guttman B, Gallagher E, Baier M. et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004; 10: 170-175 doi:10.1191/1352458504ms993oa
19 Gregson CL, Dennison EM, Compston JE. et al. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int 2014; 25: 85-95 doi:10.1007/s00198-013-2438-y
20 Binks S, Dobson R. Risk factors, epidemiology and treatment strategies for metabolic bone disease in patients with neurological disease. Curr Osteoporos Rep 2016; 14: 199-210 doi:10.1007/s11914-016-0320-5
21 McLaughlin L, Clarke L, Khalilidehkordi E. et al. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol 2018; 265: 2893-2905 doi:10.1007/s00415-018-9074-6
22 Nakao S, Yamamoto T, Kimura S. et al. Brain white matter lesions and postoperative cognitive dysfunction: a review. J Anesth 2019; 33: 336-340 doi:10.1007/s00540-019-02613-9
23 Harazim H, Stourac P, Janku P. et al. Obstetric anesthesia/analgesia does not affect disease course in multiple sclerosis: 10-year retrospective cohort study. Brain Behav 2018; 8: e01082 doi:10.1002/brb3.1082
24 Lavie C, Rollot F, Durand-Dubief F. et al. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Mult Scler 2019; 25: 591-600 doi:10.1177/1352458518763080
25 Brinkmeier H, Aulkemeyer P, Wollinsky KH. et al. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 2000; 6: 808-811 doi:10.1038/77543
26 Hambly PR, Martin B. Anaesthesia for chronic spinal cord lesions. Anaesthesia 1998; 53: 273-289
27 Hebl JR, Horlocker TT, Schroeder DR. Neuraxial anesthesia and analgesia in patients with preexisting central nervous system disorders. Anesth Analg 2006; 103: 223-228 doi:10.1213/01.ane.0000220896.56427.53
28 Ingrosso M, Cirillo V, Papasso A. et al. Femoral and sciatic nerves block (BiBlock) in orthopedic traumatologic lower limbs surgery in patients with multiple sclerosis. Minerva Anestesiol 2005; 71: 223-226
29 Su EP, Pellicci PM. The role of constrained liners in total hip arthroplasty. Clin Orthop Relat Res 2004; (420) 122-129 doi:10.1097/00003086-200403000-00017
30 Plummer DR, Haughom BD, Della Valle CJ. Dual mobility in total hip arthroplasty. Orthop Clin North Am 2014; 45: 1-8 doi:10.1016/j.ocl.2013.08.004
31 El-Husseiny M, Masri B, Duncan C. et al. Long-term results of tripolar constrained total hip arthroplasty in revision hip arthroplasty: a minimum follow-up of ten years. Bone Joint J 2019; 101-B(6 Suppl. B): S123-S126 doi:10.1302/0301-620X.101B6.BJJ-2018-1484.R1
32 Harwin SF, Mistry JB, Chughtai M. et al. Dual mobility acetabular cups in primary total hip arthroplasty in patients at high risk for dislocation. Surg Technol Int 2017; 30: 251-258
33 Celius EG. Infections in patients with multiple sclerosis: implications for disease-modifying therapy. Acta Neurol Scand 2017; 136 (Suppl. 201) S34-S36 doi:10.1111/ane.12835
34 Cadavid D, Balcer L, Galetta S. et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2017; 16: 189-199 doi:10.1016/S1474-4422(16)30377-5
35 Cadavid D, Mellion M, Hupperts R. et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2019;
36 Confavreux C, OʼConnor P, Comi G. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 247-256 doi:10.1016/S1474-4422(13)70308-9
37 van Kasteren ME, Mannien J, Ott A. et al. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis 2007; 44: 921-927 doi:10.1086/512192
38 Kirschner S, Hartmann A, Günther KP. et al. [Endoprosthetic treatment of osteoporosis-related coxarthrosis: aspects of safe patient treatment]. Orthopade 2014; 43: 353-364 doi:10.1007/s00132-013-2167-0
39 Makris A, Piperopoulos A, Karmaniolou I. Multiple sclerosis: basic knowledge and new insights in perioperative management. J Anesth 2014; 28: 267-278 doi:10.1007/s00540-013-1697-2
40 Lirk P, Birmingham B, Hogan Q. Regional anesthesia in patients with preexisting neuropathy. Int Anesthesiol Clin 2011; 49: 144-165 doi:10.1097/AIA.0b013e3182101134